A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00890292 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder
Attention Deficit Disorders With Hyperactivity

Interventions

DRUG: JNJ-31001074

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.